WILLIAM PEACOCK to Platelet Aggregation Inhibitors
This is a "connection" page, showing publications WILLIAM PEACOCK has written about Platelet Aggregation Inhibitors.
Connection Strength
0.442
-
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018 Jun 07; 378(23):2191-2201.
Score: 0.126
-
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 01; 104(9):1171-8.
Score: 0.070
-
The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. J Invasive Cardiol. 2004 Feb; 16(2):46-51.
Score: 0.047
-
A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. Am Heart J. 2003 Dec; 146(6):993-8.
Score: 0.046
-
Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI. Crit Pathw Cardiol. 2020 12; 19(4):166-172.
Score: 0.037
-
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. Stroke. 2020 08; 51(8):2386-2394.
Score: 0.036
-
Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients. Clin Cardiol. 2009 Dec; 32(12):668-75.
Score: 0.035
-
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. J Stroke Cerebrovasc Dis. 2018 Jun; 27(6):1673-1682.
Score: 0.031
-
Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2006 Jun 15; 97(12):1707-12.
Score: 0.014